Cite
HARVARD Citation
Weinblatt, M. et al. (2015). Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis research & therapy. 17 (1), pp. 1-13. [Online].